OR WAIT null SECS
This article examines trends in biopharma post-grant patent review and projects what the future holds in store.
eBooks Volume 28, Issue 14
Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee. Read this article and other articles in